Opinion|Videos|October 11, 2024
Complement Inhibitors in NMOSD
Author(s)Sean Pittock, MD
Sean Pittock, MD, discusses how complement inhibitors are positioned in the treatment landscape of neuromyelitis optica spectrum disorder, providing an overview of ravulizumab, the most recent FDA-approved treatment, including its development rationale, half-life, dosing regimen, and new signals from the recently presented 138-week long-term extension data at EAN 2024.
Advertisement
Video content above is prompted by the following:
- Where do complement inhibitors fit in the treatment landscape of neuromyelitis optica spectrum disorder (NMOSD)? Which complement inhibitors are approved for NMOSD?
- Please provide an overview of ravulizumab, the most recent FDA-approved treatment for NMOSD, the rationale for its development, half-life, and dosing regimen.
- Long-term extension (138-week) data with ravulizumab were recently presented at EAN 2024.
- Are there any new signals in the long-term extension study?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
International Committee Publishes 2024 Revisions to McDonald Diagnostic Criteria for Multiple Sclerosis
2
New Study Finds Link Between Gut Hormone GLP-1 and NMOSD Symptoms, Paving Way for Targeted Treatments
3
RELIEV-CM Pilot Study Data Further Supports ShiraTronics’ Neuromodulation Device to Treat Chronic Migraine
4
Daridorexant Provides Relief for Insomnia in Women During Menopausal Transition
5